These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29307568)

  • 21. Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.
    Agrawal L; Engel KB; Greytak SR; Moore HM
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):26-38. PubMed ID: 29258857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.
    Marous M; Bièche I; Paoletti X; Alt M; Razak AR; Stathis A; Kamal M; Le Tourneau C
    Ann Oncol; 2015 Dec; 26(12):2419-28. PubMed ID: 26371283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-biomarker co-development in oncology - 20 years and counting.
    Twomey JD; Brahme NN; Zhang B
    Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Basics of cancer immunotherapy].
    Fujioka Y; Nishikawa H
    Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
    Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
    Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune biomarkers: how well do they serve prognosis in human cancers?
    Baxevanis CN; Anastasopoulou EA; Voutsas IF; Papamichail M; Perez SA
    Expert Rev Mol Diagn; 2015 Jan; 15(1):49-59. PubMed ID: 25345403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology.
    Sobhani F; Robinson R; Hamidinekoo A; Roxanis I; Somaiah N; Yuan Y
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188520. PubMed ID: 33561505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
    Curigliano G
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First advanced course on biomarkers in molecular and immuno-oncology in the Middle East.
    Moujaess E; Khoury M; Zouein J; Eid JB; Mohty R; Kourie HR
    Future Oncol; 2021 Aug; 17(22):2831-2834. PubMed ID: 34148366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].
    Kaplon H; Dieu-Nosjean MC
    Med Sci (Paris); 2018 Jan; 34(1):72-78. PubMed ID: 29384099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction to special issue on biomarker-based clinical trial designs in oncology.
    Sargent DJ; Mandrekar S; Grothey A
    Chin Clin Oncol; 2015 Sep; 4(3):28. PubMed ID: 26408295
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials.
    Salawu A; Hernando-Calvo A; Chen RY; Araujo DV; Oliva M; Liu ZA; Siu LL
    Eur J Cancer; 2022 Sep; 173():167-177. PubMed ID: 35872510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers.
    Criscitiello C; Santangelo M; Loupakis F
    Biomed Res Int; 2018; 2018():5184075. PubMed ID: 29750158
    [No Abstract]   [Full Text] [Related]  

  • 36. Multigene Panel Testing in Oncology Practice: How Should We Respond?
    Kurian AW; Ford JM
    JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167
    [No Abstract]   [Full Text] [Related]  

  • 37. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
    Sové RJ; Jafarnejad M; Zhao C; Wang H; Ma H; Popel AS
    CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):484-497. PubMed ID: 32618119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating predictive biomarkers and classifiers into oncology clinical development programmes.
    Beckman RA; Clark J; Chen C
    Nat Rev Drug Discov; 2011 Sep; 10(10):735-48. PubMed ID: 21959287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immuno-oncology-101: overview of major concepts and translational perspectives.
    Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.